ストックスクリーナーアプリを入手
4.02
1.52%
0.06
アフターアワーズ：
4.00
-0.02
-0.50%
前日終値:
$3.96
開ける：
$4.11
24時間の取引高:
1.04M
Relative Volume:
0.88
時価総額：
$294.22M
収益：
-
当期純損益:
$-297.11M
株価収益率:
-0.7746
EPS:
-5.19
ネットキャッシュフロー:
$-216.95M
1週間 パフォーマンス:
-4.85%
1か月 パフォーマンス:
-35.47%
6か月 パフォーマンス:
-75.38%
1年 パフォーマンス:
-55.63%
1日の値動き範囲:
$3.975
$4.40
1週間の範囲:
$3.87
$4.40
52週間の値動き範囲:
$3.81
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
名前
Phathom Pharmaceuticals Inc
セクター
電話
(877) 742-8466
住所
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
4.02 | 294.22M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.42 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.85 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.65 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.97 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 開始されました | Stifel | Buy |
| 2024-01-05 | 繰り返されました | Needham | Buy |
| 2023-08-09 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-05-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2021-05-12 | アップグレード | Goldman | Sell → Neutral |
| 2021-02-17 | 開始されました | BMO Capital Markets | Outperform |
| 2021-02-02 | 開始されました | Guggenheim | Buy |
| 2020-06-26 | ダウングレード | Goldman | Neutral → Sell |
| 2019-11-20 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Goldman | Neutral |
| 2019-11-19 | 開始されました | Jefferies | Buy |
| 2019-11-19 | 開始されました | Needham | Buy |
すべてを表示
Phathom Pharmaceuticals Inc (PHAT) 最新ニュース
SNL’s Kenan Thompson brings comedy chops to Phathom’s Voquezna campaign - Medical Marketing and Media
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals To Report First Quarter 2025 Financial Results And Provide Business Update On Thursday, May 1, 2025 - marketscreener.com
Phathom Pharmaceuticals to Report First Quarter 2025 - GlobeNewswire
Phathom Pharmaceuticals Q1 Earnings Preview: Key VOQUEZNA Sales Data and Growth Strategy Reveal - Stock Titan
Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock - MSN
Shares In Phathom Pharmaceuticals Inc (PHAT) -51.97% Down, YTD - Marketing Sentinel
Phathom Pharmaceuticals (NASDAQ:PHAT) Given “Buy” Rating at Needham & Company LLC - Defense World
Alliancebernstein L.P. Has $370,000 Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
The Goldman Sachs Group Cuts Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $10.00 - Defense World
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge - simplywall.st
Phathom Pharmaceuticals (NASDAQ:PHAT) shareholders have endured a 87% loss from investing in the stock five years ago - Yahoo Finance
Phathom Pharmaceuticals appoints Ted Schroeder to board By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals appoints Ted Schroeder to board - Investing.com Australia
Phathom Pharmaceuticals appoints new board member By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals appoints new board member - Investing.com
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of D - GuruFocus
Phathom Pharmaceuticals Appoints Theodore Schroeder to Board - TipRanks
Phathom Pharmaceuticals Appoints Ted Schroeder To Its Board Of Directors - marketscreener.com
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors - GlobeNewswire
Strategic Win: Phathom Taps 30-Year Pharma Veteran to Drive VOQUEZNA Commercial Success - Stock Titan
Vanguard Group Inc. Increases Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Wellington Management Group LLP Reduces Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals’ (PHAT) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
9,100 Shares in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Acquired by KLP Kapitalforvaltning AS - Defense World
Phathom Pharmaceuticals stock hits 52-week low at $4.07 By Investing.com - Investing.com Canada
Phathom Pharmaceuticals stock hits 52-week low at $4.07 - Investing.com
Phathom Pharmaceuticals CFO Molly Henderson sells $16,739 in stock By Investing.com - Investing.com Canada
Phathom Pharmaceuticals CFO Molly Henderson sells $16,739 in stock - Investing.com
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - Yahoo Finance
Commonwealth Equity Services LLC Acquires 40,362 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Selling Phathom Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - simplywall.st
Analysts Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) PT at $22.17 - Defense World
Guggenheim Reiterates “Buy” Rating for Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
Needham & Company LLC Reaffirms Buy Rating for Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade) (PHAT) - Seeking Alpha
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
GI Disease Leader Phathom Takes Center Stage at Major Healthcare Conference - Stock Titan
Craig-Hallum Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT) - The Globe and Mail
Needham Remains a Buy on Phathom Pharmaceuticals (PHAT) - The Globe and Mail
Critical Analysis: Quoin Pharmaceuticals (NASDAQ:QNRX) & Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
When (PHAT) Moves Investors should Listen - news.stocktradersdaily.com
Change at the top for Phathom as Basta replaces Curran - BioCentury
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Phathom's New CEO Stakes Future on Stock Price and Revenue Goals - Stock Titan
Phathom Pharmaceuticals Announces Leadership Transition in 2025 - TipRanks
Phathom Pharmaceuticals Names Steven Basta CEO - MarketScreener
Phathom Pharmaceuticals Announces Leadership Succession - MarketScreener
Phathom Pharmaceuticals appoints new CEO - Investing.com
Phathom Pharmaceuticals appoints new CEO By Investing.com - Investing.com UK
Phathom Pharmaceuticals Inc (PHAT) 財務データ
収益
当期純利益
現金流量
EPS
Phathom Pharmaceuticals Inc (PHAT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Sep 10 '24 |
Option Exercise |
11.72 |
7,500 |
87,900 |
93,000 |
| Parikh Asit | Director |
Mar 13 '25 |
Buy |
4.42 |
10,000 |
44,200 |
85,500 |
| Henderson Molly | CFO and CBO |
Jan 21 '25 |
Sale |
6.59 |
6,583 |
43,371 |
93,546 |
| Nabulsi Azmi | Chief Operating Officer |
Jan 21 '25 |
Sale |
6.59 |
7,886 |
51,957 |
233,390 |
| Curran Terrie | President and Chief Executive |
Jan 21 '25 |
Sale |
6.59 |
19,109 |
125,884 |
360,465 |
| Nabulsi Azmi | Chief Operating Officer |
Dec 19 '24 |
Sale |
8.00 |
1,118 |
8,944 |
239,303 |
| Henderson Molly | CFO and CBO |
Dec 19 '24 |
Sale |
8.00 |
1,291 |
10,328 |
98,156 |
| KARBE FRANK | Director |
Dec 13 '24 |
Buy |
7.93 |
12,500 |
99,084 |
57,000 |
| Parikh Asit | Director |
Dec 13 '24 |
Buy |
8.12 |
10,000 |
81,248 |
75,500 |
| Nabulsi Azmi | Chief Operating Officer |
Jul 15 '24 |
Sale |
11.72 |
10,901 |
127,760 |
240,421 |
0.69%
21.50%
大文字化:
|
ボリューム (24 時間):